BioHealth News Archive
The FDA Approved a New Flu Treatment In Time for Flu Season – Time
The Food and Drug Administration (FDA) has approved a new antiviral influenza treatment. {iframe}http://time.com/5433403/xofluza-fda-approval/?utm_source=time.com&utm_medium=email&utm_campaign=the-brief&utm_content=2018102512pm&xid=newsletter-brief&eminfo=%7b%22EMAIL%22%3a%22FQSen6Gi%2bvP1kwg88K1Rt6yTrkkPMrpS%22%2c%22BRAND%22%3a%22TD%22%2c%22CONTENT%22%3a%22Newsletter%22%2c%22UID%22%3a%22TD_TBR_187335EB-AD8D-40AA-AE90-07F18992A3F1%22%2c%22SUBID%22%3a%2223900093%22%2c%22JOBID%22%3a%22909835%22%2c%22NEWSLETTER%22%3a%22THE_BRIEF%22%2c%22ZIP%22%3a%22%22%2c%22COUNTRY%22%3a%22USA%22%7d{/iframe}
Read More
10 impact-focused ventures enter Johns Hopkins Social Innovation Lab – Technical.ly Baltimore
Johns Hopkins’ Social Innovation Lab is kicking off a new cohort of early-stage social enterprises addressing challenges around education, health and blight, among others.…
Read More
VERALOX Therapeutics and Frederick Innovative Technology Center, Inc. – Success Story – Baltimore Business Journal
Thrombocytopenia is a big word that can carry big consequences for those struggling with rare blood disorders, especially among those using heparin to treat…
Read More
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing…
Read More
MoCo college to target economic development with new ‘RISE Zone’ – Washington Business Journal
Developers qualify if they fill buildings with biotech and cyber firms. {iframe}https://www.bizjournals.com/washington/news/2018/10/23/developers-can-now-get-md-tax-incentives-for.html{/iframe}
Read More
Altimmune CEO Bill Enright to depart – Washington Business Journal
The chief executive will stay in his role, and on the board, until his successor is appointed or early next year, whichever comes first.…
Read More
Doctors are surprisingly bad at reading lab results. It’s putting us all at risk. – The Washington Post
he man was 66 when he came to the hospital with a serious skin infection. He had a fever and low blood pressure, as…
Read More
American Gene Technologies Granted FDA Orphan Drug Designation For Phenylketonuria | American Gene Technology
American Gene Technologies (AGT), a leading gene and cell therapy company in the discovery and development of lentiviral vector based therapeutics, announces that the…
Read More
JHU startup PathoVax raises $2.75M, grows team – Technical.ly Baltimore
PathoVax, a Johns Hopkins–born startup developing a vaccine for human papillomavirus virus (HPV), raised $2.75 million in new funding, cofounder Joshua Wang said. {iframe}https://technical.ly/baltimore/2018/10/18/jhu-startup-pathovax-raises-2-75m-grows-team/{/iframe}
Read More
United Therapeutics to Develop CollPlant Technologies for 3D Bioprinted Lung Transplants – GEN
United Therapeutics will license, develop, and commercialize CollPlant Holdings’ recombinant human collagen (rhCollagen) and BioInk technology for 3D bioprinting of solid-organ scaffolds for human…
Read More
REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology…
Read More
Competing for Kids’ Health – Maryland Today
Children benefit from little of the $156 billion annual U.S. market for medical devices, but a “Shark Tank”-inspired partnership between the University of Maryland…
Read More
A New Targeted Cancer Company To Watch
Jean Cui led the invention of Pfizer's Xalkori. Now she has her own company focusing on drug-resistant cancers, and it has raised $147 million.…
Read More
Time to Reconsider Glycomimetics Inc (NASDAQ:GLYC) After Less Short Sellers? – WhatsOnThorold
Investors sentiment decreased to 1.37 in 2018 Q2. Its down 0.26, from 1.63 in 2018Q1. It dived, as 22 investors sold GlycoMimetics, Inc. shares…
Read More
Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920, a Novel Engineered CD40L Antagonist, at the 2018 ACR/ARHP Annual Meeting
Viela Bio heads to the 2018 American College of Rheumatology / Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in Chicago, 19-24 October…
Read More